Company news
Zoetis Inc. (NYSE:ZTS) news
Every Zoetis Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Zoetis to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
September 2, 2026
Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of N...
August 13, 2026
Zoetis : Receives Approval for Portela® (relfovetmab injection) in Great Britain
July 30, 2026
Zoetis Launches Portela® (relfovetmab) in Canada and the European Union
July 22, 2026
Zoetis' acquisition of Neogen Genomics requires Phase 2 review
July 17, 2026
Zoetis Launches Lenivia® (izenivetmab injection) in Canada and the European Union
July 15, 2026
Zoetis Receives European Commission Marketing Authorization for Poulvac® Procerta® HVT-ND
July 7, 2026
Zoetis to Host Webcast and Conference Call on Second Quarter 2026 Financial Results
June 25, 2026
ZTS Deadline Alert: Levi & Korsinsky Reminds Zoetis Inc. (ZTS) Investors of Securities Class Action Deadline on July 27, 2026
June 10, 2026
Labaton Keller Sucharow LLP Files Securities Class Action Against Zoetis, Inc. and Certain of Its Executives
May 27, 2026
Zoetis Declares Third Quarter 2026 Dividend
May 20, 2026
ZTS Investor Alert: Levi & Korsinsky Investigates Zoetis (ZTS) for Potential Securities Fraud
May 20, 2026
Zoetis Announces First Quarter 2026 Results
May 7, 2026
Techcyte Announces $15 Million Capital Raise Led by Van Tuyl Companies to Support Growth and Path to Profitability
April 30, 2026
Zoetis Equine Renews Title Sponsorship for the 2026 Horses for Mental Health Campaign
April 6, 2026
Zoetis to Host Webcast and Conference Call on First Quarter 2026 Financial Results
April 2, 2026
Zoetis to Participate in the KeyBanc Capital Markets Healthcare Forum
March 12, 2026
Zoetis expands Human-Animal Bond Certification scholarship to include veterinary technician students
March 10, 2026
Neogen Announces Sale of Genomics Business to Zoetis
March 2, 2026
Zoetis to Acquire Animal Genomics Business from Neogen®, Accelerating Precision Animal Health Innovation
March 2, 2026
Zoetis to Participate in the Bank of America Securities 2026 Animal Health Summit
February 24, 2026
Zoetis Reports Fourth Quarter and Full Year 2025 Results
February 12, 2026
Zoetis Declares Second Quarter 2026 Dividend
February 5, 2026
Zoetis to Host Webcast and Conference Call on Fourth Quarter and Full Year 2025 Financial Results
December 30, 2025
Zoetis to Participate in the 44th Annual J.P. Morgan Healthcare Conference
December 18, 2025
Zoetis Announces Pricing of $1.75 Billion Convertible Senior Notes Offering
December 16, 2025
Zoetis Announces Proposed $1.75 Billion Convertible Senior Notes Offering
December 15, 2025
Zoetis Declares First Quarter 2026 Dividend; Board Approves 6% Payment Increase
December 11, 2025
Zoetis Receives Health Canada Approval for Portela™(relfovetmab injection) to Alleviate Pain Associated with Osteoarthritis in Cats
December 5, 2025
Zoetis Highlights R&D Leadership and Long-Term Growth Opportunity at Innovation Webcast
December 2, 2025
Zoetis Receives European Commission Marketing Authorization for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA)...
November 26, 2025
Zoetis to Participate in the Piper Sandler 37th Annual Healthcare Conference
November 20, 2025
Zoetis to Host Innovation Webcast
November 19, 2025
Zoetis Announces Third Quarter 2025 Results
November 4, 2025
Zoetis Announces Retirement of Rob Polzer at the End of 2025 and the Appointment of Kevin Esch as President of Research & Development for...
November 3, 2025
Zoetis Receives European Commission Marketing Authorization for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis i...
October 29, 2025
Zoetis Appoints Stephanie Tilenius to its Board of Directors
October 28, 2025
Zoetis Announces Health Canada Approval of Lenivia® (izenivetmab injection) for Alleviation of Osteoarthritis (OA) Pain in Dogs
October 15, 2025
Zoetis Receives Positive Opinion from CVMP for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs
October 10, 2025
Zoetis Declares Fourth Quarter 2025 Dividend
October 9, 2025
Zoetis Receives Conditional Approval for Dectomax®-CA1 Injectable for the Prevention and Treatment of New World Screwworm Myiasis in Cattle
September 30, 2025
Zoetis to Host Webcast and Conference Call on Third Quarter 2025 Financial Results
September 23, 2025
Zoetis Receives Positive Opinion from CVMP for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats
September 12, 2025
Zoetis to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
August 27, 2025
Zoetis Announces Pricing of $1.85 Billion of Senior Notes
August 11, 2025
Zoetis Announces Second Quarter 2025 Results, Raises Full Year 2025 Outlook
August 5, 2025
Zoetis to Host Webcast and Conference Call on Second Quarter 2025 Financial Results
July 1, 2025
Zoetis Releases 2024 Sustainability Progress Update
June 5, 2025
Dr. Mark Stetter Elected to Zoetis Board of Directors
May 22, 2025
Zoetis Declares Third Quarter 2025 Dividend
May 21, 2025